Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer MRD testing helps clinicians track a patient's risk ...

LabCorp is now offering a new FDA-approved test that will improve therapy for certain colorectal cancer patients, the Burlington-based company announced on Friday. QIAGEN’s therascreen® KRAS RGQ PCR ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Regular preventive screenings can make a life-changing difference—especially when it comes to cancer. According to the American Cancer Society, colorectal cancer is the third-leading cause of ...

FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...